Cipla (CIPLA) Q1 26/27 earnings summary

Executive summary

• Achieved highest-ever Q1 revenue at INR 7,119 crore, up 2% YoY, with strong growth in India and steady performance across global markets.

• One India business posted 12% YoY growth, led by chronic therapies and new launches; North America revenue reached $162 million, maintaining leadership in U.S. albuterol MDI market.

• Launched several new products in India and North America, including the first AB-rated gVentolin in the US.

• Unaudited standalone and consolidated financial results for the quarter ended 30th June 2026 were approved and released, reflecting continued operational and financial performance.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was ₹7,119.28 crore, up from ₹6,541.20 crore in Q1 FY26 and ₹6,957.47 crore in Q4 FY26.

• EBITDA margin (excluding other income) at 16.7% for the quarter; gross margin at 62.5%, impacted by product mix, war-related costs, and higher inventory write-offs.

• Profit after tax stood at INR 789 crore (11% of sales); R&D investments at INR 486 crore (6.8% of revenue).

• Net cash equivalent balance at INR 9,494 crore after dividend payment of INR 1,050 crore; debt including lease liabilities at INR 600 crore.

• Basic and diluted EPS (consolidated) for the quarter were ₹9.77 and ₹9.76, respectively.

Outlook and guidance

• North America expected to continue sequential growth, driven by upcoming launches including three respiratory assets (e.g., generic ADVAIR) and a key peptide.

• U.S. business targets $1 billion exit run rate for FY 2027, contingent on successful launches and scale-up of Ventolin.

• EBITDA margin guidance for FY 2027 remains at 18.5%-20%, dependent on new product approvals and launches.

• Ongoing focus on ESG goals, including renewable energy and water neutrality targets for manufacturing.

• The company continues to expect a favorable outcome in ongoing regulatory litigations and has not made provisions for certain demand notices.